SCHEMBL19348683

SCHEMBL19348683

Cc1ccc(OP(=O)(F)Br)c(C)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
HPGD P15428 6/20 0.40
CYP3A4 P08684 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
ACHE P22303 1/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
TSHR P16473 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPK1 P28482 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
CA9 Q16790 1/20 0.34
HCRTR1 O43613 1/20 0.34
MRGPRX4 Q96LA9 1/20 0.34
NPC1 O15118 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19348756 0.85 MEN1 (0.42) MEN1KMT2AHPGDCYP3A4CYP1A2
SCHEMBL19348792 0.81 MEN1 (0.41) MEN1KMT2AHPGDCYP3A4CYP1A2
SCHEMBL29349879 0.80 CYP3A4 (0.50) MEN1KMT2AHPGDCYP3A4CYP1A2
SCHEMBL108984 0.80 CYP3A4 (0.50) MEN1KMT2AHPGDCYP3A4CYP1A2
SCHEMBL14229933 0.79 MEN1 (0.44) MEN1KMT2AHPGDCYP3A4CYP1A2
SCHEMBL6862372 0.77 MEN1 (0.42) MEN1KMT2AHPGDCYP3A4CYP1A2
SCHEMBL497308 0.77 HPGD (0.45) MEN1KMT2AHPGDCYP3A4CYP1A2
SCHEMBL5667322 0.77 HPGD (0.42) MEN1KMT2AHPGDCYP3A4CYP1A2
SCHEMBL109597 0.77 INPPL1 (0.52) HPGDLMNAPOLBTP53
SCHEMBL3621142 0.77 HPGD (0.42) MEN1KMT2AHPGDCYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3222624-B1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME CENTRAL GLASS CO LTD (JP) 2019-11-06 EP disclosed
US-10287165-B2 Imidic acid compound having divalent anion and process for producing the same CENTRAL GLASS CO., LTD. (JP) 2019-05-14 US disclosed
EP-3222624-A1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME Central Glass Co., Ltd. (JP) 2017-09-27 EP disclosed
US-20170267528-A1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME CENTRAL GLASS CO., LTD. (JP) 2017-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170267528-A1 IMIDIC ACID COMPOUND HAVING DIVALENT ANION AND PROCESS FOR PRODUCING THE SAME CA2, CA6, CHRM1 MEN1 233/4885KMT2A 3876/4885HPGD 3828/4885
US-10287165-B2 Imidic acid compound having divalent anion and process for producing the same CA2, CA6, CHRM1 MEN1 233/4885KMT2A 3876/4885HPGD 3828/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.